LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcomes Results) trial revealed that patients who received liraglutide had a lower risk of the primary composite outcome as listed above, cardiovascular death, death from any cause, and microvascular events than the placebo group [10]
Ipamorelin Peptide Overview Ipamorelin Peptide Overview Ipamorelin is a synthetic pentapeptide classified as a growth hormonereleasing peptide (GHRP)
Mean change in HbA1c to end of treatment according to baseline eGFR (truncated between 5th and 95th percentile) in SUSTAIN 46, and 10, and PIONEER 5 and 6
Day 02: Lima City Tour Breakfast at the hotel
Directing patients to these resources increases medication affordability and helps them stay on treatment, which improves your clinical outcomes and patient retention
Vigorous shaking can physically shear and destroy the delicate peptide chains